Flagship launches Senda Biosciences with $88M in backing, looking to pioneer the field of 'Intersystems Biology'
Flagship Pioneering has a fresh company out this week, one that aims to lay the groundwork for a whole new discipline.
Senda Biosciences launched Wednesday with $88 million in Flagship cash. The goal? Gain insights into the molecular connections between people and coevolved nonhuman species like plants and bacteria, paving the way for “Intersystems Biology.”
Guillaume Pfefer has been tapped to run the show, a 25-year biotech veteran who comes from GSK after leading the development of the company’s shingles vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.